Septerna, Inc. (SEPN) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 42 days, typically, give or take 17 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Mon, Nov 9, 2026after close 40 8-K
Q2 FY2026Mon, Aug 10, 2026after close 41 8-K
Q1 FY2026Mon, May 11, 2026after close 41 8-K
Q4 FY2025Mon, Mar 9, 2026after close 68 8-K
Q3 FY2025Mon, Nov 10, 2025before open 41 8-K
Q2 FY2025Mon, Aug 11, 2025after close 42 8-K
Q1 FY2025Thu, May 15, 2025after close 45 8-K
Q4 FY2024Thu, Mar 27, 2025before open 86 8-K

What they guided beta

Q3 FY2026 "Phase 1 Clinical Trial for PTH1R Agonist SEP-479 Ongoing; SAD / MAD Data Expected in Q1 2027 Plans to Initiate Phase 1 Clinical Trial of Newly Selected Oral TSHR NAM Development Candidate SEP-204 in Q1 2027 Cash Position of $565.2 Million Expected to Support Operating Plans at Least into mid-2029 SOUTH SAN FRANCISCO, Calif. – November 09, 2026 – Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted pipeline progress and anticipated milestones and reported financial results for the thir" exhibit
Q3 FY2026 "“With Phase 1 data for SEP-479 and the initiation a Phase 1 trial of SEP-204 expected in the first quarter of 2027, we are moving closer to realizing our ambition to translate our GPCR expertise into differentiated oral medicines for patients with significant unmet needs.”" exhibit
Q3 FY2026 "SEP-479 PTH1R Agonist for Hypoparathyroidism: o Septerna’s Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial of SEP-479, an oral small molecule PTH1R agonist in development for hypoparathyroidism, is ongoing in healthy volunteers, with data expected in the first quarter of 2027." exhibit
Q3 FY2026 "Additional details are available in the data release . o Following the successful completion of the remaining preclinical development activities, Septerna anticipates initiating a Phase 1 clinical trial for SEP-204 in healthy volunteers in the first quarter of 2027." exhibit
Q3 FY2026 "Septerna expects its existing cash runway to fund operations at least into mid-2029." exhibit
Q2 FY2026 "Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expected in Q1 2027 Cash Position of $516.5 Million Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif. – August 10, 2026 – Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted pipeline progress and anticipated milestones and reported financial results for the second quarter ended Ju" exhibit
Q2 FY2026 "As a result, Septerna expects to report Phase 1 data from both the SAD and MAD cohorts in the first quarter of 2027. o During the quarter, the Company presented the first detailed preclinical characterization of SEP-479 in an oral presentation at ENDO 2026, highlighting data supporting its potential as a differentiated, once-daily oral treatment for hypoparathyroidism." exhibit
Q2 FY2026 "Septerna expects its existing cash runway to fund operations at least into 2029." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/SEPN
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/SEPN

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

SEPN earnings date badge

HTML

<a href="https://veritasdata.dev/company/SEPN/"><img src="https://veritasdata.dev/embed/SEPN.svg" alt="SEPN earnings date" width="240" height="56"></a>

Markdown

[![SEPN earnings date](https://veritasdata.dev/embed/SEPN.svg)](https://veritasdata.dev/company/SEPN/)

Script

<script async src="https://veritasdata.dev/embed/SEPN.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/SEPN"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.